Premium
Febuxostat: new xanthine oxidase inhibitor for gout
Author(s) -
Chaplin Steve,
Doherty Michael
Publication year - 2011
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.711
Subject(s) - febuxostat , xanthine oxidase inhibitor , gout , medicine , xanthine oxidase , uric acid , hyperuricemia , pharmacology , biochemistry , enzyme , chemistry
Febuxostat (Adenuric) is a xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia when urate deposition has already occurred. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Professor Michael Doherty discusses its place in the treatment of gout. Copyright © 2011 Wiley Interface Ltd